JPS5826820A - Hypotensive substance - Google Patents
Hypotensive substanceInfo
- Publication number
- JPS5826820A JPS5826820A JP56125498A JP12549881A JPS5826820A JP S5826820 A JPS5826820 A JP S5826820A JP 56125498 A JP56125498 A JP 56125498A JP 12549881 A JP12549881 A JP 12549881A JP S5826820 A JPS5826820 A JP S5826820A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- shiitake
- substance
- blood pressure
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は高血圧症の予防及び治療に関する4のである。[Detailed description of the invention] The present invention relates to the prevention and treatment of hypertension.
さらに詳しくは、シイタケよシ抽出、処理、精製して得
られたシイタケ抽出液中性部からなる、血圧降下作用を
有する物質に関するものである。More specifically, the present invention relates to a substance having a blood pressure lowering effect, which is composed of the neutral part of a Shiitake extract obtained by extracting, processing, and purifying Shiitake mushrooms.
高血圧症は我−の高都令層疾病の115を占める、−民
にとって直火な疾患の−っである。Hypertension accounts for 115 of the diseases of the high-income class in Japan, and is a disease of direct concern to the people.
血圧降下剤の必要条件は習慣性の低いこと、連用−作用
の低いこと、安全域の広いこと、1回投与で半日以上の
効果が期待できること、心1搏出瞼、脳、I#城などの
血流が減少しないことなどである。しかしながら、従来
これらを満足するものは見通らないのが現状であり、新
薬の開発が期待される分野である。The requirements for antihypertensive drugs are low habit-forming, low long-term action, wide safety margin, expected effectiveness for more than half a day with a single administration, heart, eyelid bulge, brain, I # castle, etc. The blood flow of the patient does not decrease. However, the current situation is that there is no drug in sight that satisfies these requirements, and this is an area where the development of new drugs is expected.
本発明者らは、種々の薬効を有し、古くから不老長噌の
妙薬として珍重されているシイタケの血圧降下作用に着
目したが、シイタケの場合、特有の強い臭気によシ、服
用継続すると、食欲減退、爽には嘔吐を催す場合もあり
、しかも1回の投与に多量を要し、血圧降下剤として必
要な長期の連用を困離にするなどの問題があることが判
明した。The present inventors focused on the blood pressure-lowering effect of shiitake mushrooms, which have various medicinal effects and have been prized as an elixir for longevity since ancient times. It has been found that there are problems such as decreased appetite and vomiting in some cases, and that a large amount is required for one administration, making long-term continuous administration necessary as an antihypertensive agent difficult.
そこで本発明者らはこのような問題を解決すべく研究を
重ねた結果、シイタケの水性溶媒抽出液をイオン交換樹
脂処理して得られた抽出液中性部が強い血圧−工作用を
有し、しかもシイタケ特有の臭気が消失し、血圧降下剤
として満足すべきことを見い出し本発明に刺違した。As a result of repeated research to solve these problems, the present inventors found that the neutral part of the extract obtained by treating the aqueous solvent extract of shiitake mushrooms with an ion exchange resin has a strong blood pressure control effect. Moreover, the odor characteristic of shiitake mushrooms has disappeared, and they have found that they are satisfactory as antihypertensive agents, and have incorporated them into the present invention.
本発明の目的は、習慣性、副作用が低く、長期の連用か
り能である、高血圧症予防及び治療用に適した物質を得
ることにある。An object of the present invention is to obtain a substance suitable for the prevention and treatment of hypertension, which has low habit-forming properties, low side effects, and can be used over a long period of time.
本発明はシイタケを水性溶媒で抽出後、抽出液をイオン
交懐樹ll&iで処理し、得られた抽出液中性Stカラ
ムクロマドグ′:)7によシ精製もしくはせずに得られ
た血圧降下作用を有する物質を提供するもので、皺物質
と薬剤もしくは食品としで許容されつる虫体とを含有す
る処方物は、高血圧症予防及び治療剤として通している
。In the present invention, after extracting shiitake mushrooms with an aqueous solvent, the extract is treated with an ion exchanger, and the resulting extract is purified with or without purification by a neutral St column chromadog':)7. Formulations containing rugose substances and vine bodies that are acceptable as drugs or foods, providing substances with a lowering effect, have been passed as antihypertensive prophylactic and therapeutic agents.
本発・明におけるシイタケとは、主としてシイ、ナン、
クリ、シブ、クヌギ等カシワ科及びカバツキ科の朽ち木
に寄生する四担子−dl141醒族にJ1!4−る1で
あp1子実体、培養−糸体を用い、これらは必要に応じ
て切断、摩砕尋を何なって表−積を増大させ抽出効率を
上げるようにする。In the present invention, shiitake mainly refers to shiitake, naan,
J1!4-ru1 p1 fruiting bodies and thread bodies were used for the four-basidium-dl141 xing group that parasitizes decayed trees of the oak family and birchaceae, such as chestnut, oak, oak, etc., and these were cut as necessary. What is the purpose of milling to increase surface area and increase extraction efficiency?
抽出は水性溶媒との振盪抽出、連続抽出、あるいは攪拌
下に加熱抽出することによって目的とする血圧降下作用
物質を抽出することができる。抽出溶媒として用いる水
性溶媒とは水を主体とした溶媒であって1、水単独ある
いは水と混和しつるか、水に静解しつる鎗の有機溶媒例
えばメタノール、エタノール、インプロパツール、アセ
トン、酢酸エチルなどを含有−(る溶媒であるが、水と
エタノールの混合溶媒(エタノール60−80容Jll
係)を用いるのが良く、経済的には一旦水単独で抽出後
、上記混合溶媒で処理するのがよい。The desired blood pressure lowering agent can be extracted by shaking extraction with an aqueous solvent, continuous extraction, or heating extraction with stirring. The aqueous solvent used as the extraction solvent is a solvent mainly composed of water. 1. Water alone, or an organic solvent that is miscible with water or dissolved in water, such as methanol, ethanol, impropatol, acetone, Although it is a solvent containing ethyl acetate etc., a mixed solvent of water and ethanol (ethanol 60-80 volumes)
Economically, it is best to extract with water alone and then treat with the above-mentioned mixed solvent.
次に抽出液を適宜a縮した債、イオン交換樹脂を用いて
常法に従って処理し抽出液中性部を得る。Next, the extract is treated in a conventional manner using a suitable a-condensed bond and an ion exchange resin to obtain a neutral part of the extract.
使用するイオン交換樹脂としてはスルホン酸基をもった
強酸性のもの、カルボキシル基ヲ持つ危弱酸性のもの、
第4級アンモニウム篇を持った強塩基性のもの、第1〜
第3級アイノ基を持つ九弱塩基性のもののいずれを使用
しても東いが、強酸性及び弱塩基性のイオン交換樹脂の
組合せが好オし7く、抽出一層液を強酸性イオン交換−
+1−と弱塩基性イオン交換樹脂を充填【、九カラムを
通過させるか、バッチ法によりイオン交換樹脂と攪拌静
置することにより不純物をイオン交換4M脂に吸着除去
し、流出し九中性部を一編し、血圧降下有効成分を得る
。このようにして得られ友中性部はこの11でも十分血
圧降下作用を示すがなお無効ないし効力の−い成分を含
有しCいるので、更に吸着クロマトグラフィーによって
?111!処堤して、高純度の血圧降下成分を分離、採
取することが出来る。丁なわち、中性部を適宜橋縮する
か蒸発乾固した後、水に溶解し、各種吸着剤に吸着後、
水性溶媒にて溶出させる。ここで使用する吸着剤としで
は、活性炭、活性炭−セライト、セライト、アルiナ、
シリカゲル、デンプン、セルロース等が挙げられ、単独
あるいは2種以上混合して用いてもよい。次に吸着剤に
吸着した有効成分は前述の各種水性lIi!l媒にて、
尋出され、溶出液を一編することによシ有効成分を白色
粉末として分離、採取することができる。The ion exchange resins used are strongly acidic ones with sulfonic acid groups, weakly acidic ones with carboxyl groups,
Strongly basic substances with quaternary ammonium, No. 1~
Although it is possible to use any weakly basic resin with a tertiary aino group, it is preferable to use a combination of strongly acidic and weakly basic ion exchange resins. −
Filled with +1- and weakly basic ion exchange resin [, impurities are adsorbed and removed by ion exchange 4M fat by passing through a nine column or stirring and standing with ion exchange resin in a batch method, and flow out to form nine neutral parts. to obtain the blood pressure lowering active ingredient. Although the neutral part obtained in this way exhibits a sufficient blood pressure lowering effect with 11, it still contains ineffective or ineffective components, so it can be further analyzed by adsorption chromatography. 111! It is possible to separate and collect highly pure blood pressure-lowering components. After the neutral part is appropriately bridged or evaporated to dryness, it is dissolved in water and adsorbed on various adsorbents.
Elute with an aqueous solvent. The adsorbents used here include activated carbon, activated carbon-Celite, Celite, Alina,
Examples include silica gel, starch, cellulose, etc., and they may be used alone or in combination of two or more. Next, the active ingredients adsorbed on the adsorbent are the various aqueous lIIi! In l medium,
By extracting the extract and collecting the eluate, the active ingredient can be separated and collected as a white powder.
このようにして得られたシイタケの本発明の血圧降下作
用物質は以下の事項により特徴づけられるが、純粋な単
一物質ではなく、゛下dピ諸性質からみて、少#a拳を
主成分とする混合物質であると考えられる。The antihypertensive agent of the present invention obtained from shiitake mushrooms obtained in this way is characterized by the following points, but it is not a pure single substance, and from the viewpoint of various properties, the main component is It is considered to be a mixed substance.
l)工Rスペクトル 図1に示すとおりである。l) Engineering R spectrum As shown in FIG.
1)UVスペクトル 図2に示すとおりである。1) UV spectrum As shown in FIG.
m)Ckb。m) Ckb.
図5に示すとおりである。As shown in FIG.
IV)TLO 図4に示すとおシである。IV) TLO This is shown in FIG.
■)各種定性反応
ニンヒドリン反応−−−一−噂性
α−す7ト一ル反応−−−−−性
エルソン争モルガン&応−Hfjh性
十紀の41積で特徴づけされるシイタケ抽出液中性部は
、そのままで血圧降下作用物質として優れCJ、−如、
そのまま、あるいは水に溶解させて投与できるが、薬剤
もしくは食品として計容されうる担体、例えば抗論血症
峨、抗コレステロール薬、血糖低下剤などの薬剤あるい
は、果汁、来汁番料、甘味料等の風味剤と混合して、血
圧低下効果あるいは嗜好性を高めることができる。父、
゛錠剤、カプセル、トν−テ、丸薬、米粒、粉末、シロ
ップ、注射薬等の形態として投与することができる。■) Various Qualitative Reactions Ninhydrin Reaction - Rumored α-S7 Tol Reaction - In Shiitake Mushroom Extract Characterized by 41 Products of Elson, Morgan & Hfjh, Juki The genital area is excellent as a blood pressure lowering substance as it is, CJ, - like,
Carriers that can be administered as they are or dissolved in water, but can be packaged as medicines or foods, such as medicines for anti-inflammatory drugs, anti-cholesterol drugs, hypoglycemic agents, or fruit juices, seasoning agents, sweeteners It can be mixed with flavoring agents such as, to enhance the blood pressure lowering effect or palatability. father,
It can be administered in the form of a tablet, capsule, tote, pill, rice grain, powder, syrup, injection, etc.
本発明のシイタケ抽出物中性部を含む処方物は少量で顕
著な血圧低下効果を発揮し、習慣性、削作用が低く、長
期の連用が可能である。The formulation containing the neutral part of the shiitake mushroom extract of the present invention exhibits a remarkable blood pressure lowering effect even in a small amount, has low habit-forming and depleting effects, and can be used continuously for a long period of time.
次に本発明の効果を実施例をあげて説明する。Next, the effects of the present invention will be explained by giving examples.
v4麿例
市販乾燥シイタケ傘部を裁断し、70℃で2時間乾燥さ
せた後、乾燥シイタケに対し、10倍重量の水を加え一
夜放置して抽出し、それをロータリーエバポレーターに
Cm縮した。Commercially available dried shiitake caps were cut into pieces and dried at 70°C for 2 hours, then 10 times the weight of water was added to the dried shiitake mushrooms, left to stand overnight for extraction, and the resulting product was compressed using a rotary evaporator.
抽出#線源に5倍容のエタノールを加えC1生じた沈澱
を除去した後、75僑エタノール抽出1[tliIIl
イオン交洟樹13交換 (アンバー2イトエR−120
)、婆イオン交洪樹脂CアンバーライトエR−451を
充填したカシムに順次通過させて抽出箪中性部を得た。Extraction # After adding 5 times the volume of ethanol to the radiation source and removing the precipitate produced, 75% ethanol extraction 1 [tliIIl
Aeon Exchange 13 Exchange (Amber 2 Itoe R-120
), the mixture was sequentially passed through a cassym filled with ion exchange resin C Amberlite R-451 to obtain a neutral part.
父、比較のため工R−120@着部を2慢アンモニア水
、目し一45v&着部を0.5N酢酸でそれぞれ連出さ
せ、それぞれ抽出液塩基性区分、抽出液練性区分を得た
。For comparison, we extracted R-120@Kibu with 2-chloride ammonia water and 45V of Meshii and 0.5N acetic acid to obtain the extract basicity category and the extract kneadability category, respectively. .
乾燥シイタケ100tより見られた各区分の[庫直緻は
以下の通9であった。The freshness of each category found from 100 tons of dried shiitake mushrooms was as follows:
水抽出部40.1F 751工タノール沈澱部14.
4f 塩基+!P区分5.72 酸性区分0.42中
性区分104t なお、中性区分は白色、無臭でめった
。Water extraction section 40.1F 751 ethanol precipitation section 14.
4f base+! P category: 5.72 Acidic category: 0.42 Neutral category: 104 tons The neutral category was white and odorless.
各区分を用い、某公定憬関にで高皿圧自然発耐うッ)
(8HR1ii史用1″C皿圧低F動物実験を行なった
。Using each category, it can withstand high plate pressure spontaneously under a certain official test)
(8HR1ii historical 1″C dish pressure low F animal experiment was conducted.
BHNはテストの全期間で通じ、26±2℃、湿度50
上10−に′9!調された動物室で固型飼料を用い(−
嗣育した。各区分は、シイタケ50を相当mt水1tに
鋳解し、水の代わシに自由摂取させた。BHN was maintained during the entire test period at 26 ± 2°C and humidity 50°C.
Top 10-'9! Using solid food in a prepared animal room (−
I inherited it. For each class, 50 pieces of shiitake mushrooms were dissolved in 1 ton of equivalent mt water, and the mushrooms were given ad libitum instead of water.
く血圧上昇期のsnhでのテスト〉
12週齢まで水で予(1kl+411fした8m(Hに
対し12〜15逓齢のl1J1試験溶液にC−胃し、さ
らに水に戻しC16週齢まで嗣青し、血圧と体シの変化
を見た。Test on SNH during the period of increased blood pressure〉 Inject into the l1J1 test solution of 12 to 15 years of age with water (1 kl + 411f for 8 m) until 12 weeks of age, and then return to water and continue to test with water until 16 weeks of age. We then observed changes in blood pressure and physical condition.
結果は下記表−1に示すとおりでToプ、水抽出部及び
中性区分にかなり、酸性区分に若干の血圧上昇防止効果
が見られた。The results are shown in Table 1 below, and a significant effect of preventing blood pressure increase was observed in the Topo, water-extracted and neutral categories, and a slight effect in preventing blood pressure increase in the acidic category.
く高血圧u)i8 HRでのテスト〉
次に血圧上昇期のテストで効果のあった区分についC^
血血圧クラット血圧低下効果t−試験した。25遇齢ま
で水で予備飼育し′C高血圧となった8)IBに対し、
25〜27遁齢の間、試験廖液にて飼育し、さらに水に
戻して28遇齢まで一冑し、血圧と体慮の変化を見た。High blood pressure u) i8 HR test> Next, let's talk about the categories that were effective in the test during the period of increased blood pressure.
The effect of lowering blood pressure in rats was tested. 8) For IB, which developed high blood pressure after being pre-fed with water until the age of 25,
The animals were kept in a test solution from 25 to 27 years of age, and then returned to water until they were 28 years of age, and changes in blood pressure and physical condition were observed.
−結果は下記表−2に示すとおシであり、中性区分にの
み、顕著な血圧低下効果が見られた。- The results are shown in Table 2 below, and a significant blood pressure lowering effect was observed only in the neutral category.
以上の◆よりシイタケ抽出物中の中性部は、血圧上昇防
止及び血圧低下作用を有すると菖える。From the above ◆, it can be seen that the neutral part in the shiitake mushroom extract has the effect of preventing an increase in blood pressure and lowering blood pressure.
父、8i1Rの体直、外嵌等にはIulら異′イが見ら
れず、連用側作用も少ないものと考えられる。No abnormalities such as Iul's were observed in the straightness of the body, external fit, etc. of the father, 8i1R, and it is thought that there is little effect on the side of continuous use.
従って、本発明のシイタケ抽出物中性部を含む処方物は
為血圧症予防及び治療用製剤として適していると菖える
。Therefore, the formulation containing the neutral part of the shiitake extract of the present invention is suitable as a preparation for preventing and treating hypotension.
図1はシイタケ抽出液中性部の赤外S吸収スベクル(K
Br襄剤洗剤法示し、図2はシイタケ抽出液中性部紫外
S吸収スペクトルを示し、図5はシイタケ抽出液中性部
のTMB化ガスクロマトグラムを示し、図4はシイタケ
抽出液中性部の薄層クロマトグラフィーによる分析結果
を示す。
特許出願人
旭電化工業株式金社
手続補正書C方式〕
昭和57年2月25日
特許庁長官島田春樹殿
1、事件の表示
特願昭56−125498号
2、発明の名称
血圧降下作用を有する物質
3、補正をする者
事件との関係 特許出願人
(01g)旭電化工業株式会社
4、代理人
東京都港区赤坂九丁目6番29号
パシフィック乃木坂601号
昭和57年1月46日(発送日)
6、補正の対象 図 t
7、補正の内容
別紙添付の通り、図面を、けい線枠線等のない白色のト
レーシングペーパーを用い、製画を用いて鮮明に描いた
図面に補正(内存に変更なし)0以 上Figure 1 shows the infrared S absorption spectrum (K) of the neutral part of the shiitake extract.
Figure 2 shows the UV S absorption spectrum of the neutral part of the shiitake extract, Figure 5 shows the TMB gas chromatogram of the neutral part of the shiitake extract, and Figure 4 shows the spectrum of the neutral part of the shiitake extract. The results of analysis by thin layer chromatography are shown. Patent Applicant Asahi Denka Kogyo Co., Ltd. Procedural Amendment Form C] February 25, 1980 Haruki Shimada, Commissioner of the Japan Patent Office 1, Indication of the case Patent Application No. 125498/1982 2, Name of the invention Has a blood pressure lowering effect Substance 3, Relationship with the amended person case Patent applicant (01g) Asahi Denka Kogyo Co., Ltd. 4, Agent No. 601 Pacific Nogizaka, 6-29 Akasaka 9-chome, Minato-ku, Tokyo January 46, 1982 (shipped) 6. Target of correction Figure t 7. Details of correction As shown in the attached sheet, the drawing has been corrected to a drawing that was clearly drawn using a drafting method using white tracing paper with no cross-section lines, etc. (no change in existence) 0 or more
Claims (1)
で処理し、得られた抽出液中性部をカラムクロマトグラ
フにょ如精製もしくはせず番ζ得られた、血圧降下作用
を有する物質。After extracting shiitake mushrooms with an aqueous medium, the extract is treated with an ion exchange resin, and the neutral part of the resulting extract is purified using column chromatography to obtain a substance that has a hypotensive effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56125498A JPS5826820A (en) | 1981-08-11 | 1981-08-11 | Hypotensive substance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56125498A JPS5826820A (en) | 1981-08-11 | 1981-08-11 | Hypotensive substance |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5826820A true JPS5826820A (en) | 1983-02-17 |
JPH0357082B2 JPH0357082B2 (en) | 1991-08-30 |
Family
ID=14911589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56125498A Granted JPS5826820A (en) | 1981-08-11 | 1981-08-11 | Hypotensive substance |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5826820A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006257007A (en) * | 2005-03-16 | 2006-09-28 | Nagase & Co Ltd | Angiotensin converting enzyme inhibitor |
JP2006265179A (en) * | 2005-03-24 | 2006-10-05 | Noda Shokukin Kogyo Kk | Antihypertensive agent, and food and drink |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006195009A (en) | 2005-01-11 | 2006-07-27 | Fuji Photo Film Co Ltd | Hologram recording method, hologram recording device and hologram recording medium |
JP4373383B2 (en) | 2005-08-24 | 2009-11-25 | 富士フイルム株式会社 | Optical recording method, optical recording apparatus, optical recording medium, and optical recording / reproducing method |
JP2007072192A (en) | 2005-09-07 | 2007-03-22 | Fujifilm Corp | Optical recording medium, and method for producing the same |
-
1981
- 1981-08-11 JP JP56125498A patent/JPS5826820A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006257007A (en) * | 2005-03-16 | 2006-09-28 | Nagase & Co Ltd | Angiotensin converting enzyme inhibitor |
JP2006265179A (en) * | 2005-03-24 | 2006-10-05 | Noda Shokukin Kogyo Kk | Antihypertensive agent, and food and drink |
Also Published As
Publication number | Publication date |
---|---|
JPH0357082B2 (en) | 1991-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1022022B1 (en) | Composition for inhibiting increase of blood sugar level or lowering blood sugar level | |
CA2486915C (en) | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng | |
EP2520305B1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
WO2006056129A1 (en) | Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof | |
JPS60214741A (en) | Hypoglycemic agent | |
KR100450021B1 (en) | Extracts of ginkgo biloba leaves with reduced 4′omethylpyridoxine and bioflavones content | |
DE2710327A1 (en) | CARCINOSTATIC AGENT | |
EP0216936B1 (en) | Novel tannin composition | |
CN108815218B (en) | Pharmaceutical composition and use thereof | |
JPS5826820A (en) | Hypotensive substance | |
CN101032532B (en) | Medicine composition including active substrates extracted from Sang Huang, the preparing method and the application in the producing of medicine thereof | |
CN110664860B (en) | Composition for enhancing immunity and preparation method thereof | |
JPH0789863A (en) | Isolation refining method for ginsenoside re and antiarhythmic agent mainly composed of compound | |
CN114404462B (en) | Composition and application thereof in preparation of medicine for treating gastric injury and/or gastric ulcer | |
CN114224934B (en) | Eucommia ulmoides extract for improving microcirculation | |
KR20070026329A (en) | Use of plant parts of prickly pear(opuntia)and/or extracts thereform for the treatment of depressions | |
CN106962910B (en) | Health-care composition for reducing blood pressure | |
KR20230039856A (en) | Anti-inflammatory composition comprising complex ginsenoside composition | |
JP3323765B2 (en) | Cell adhesion inhibitor | |
CN112472725A (en) | Brown algae extract and its application | |
US4080442A (en) | Disaccharide derivatives used in the treatment of hepatic diseases | |
JP3320879B2 (en) | Anti-gastrin agent | |
KR20050097710A (en) | Modified ginsenoside mixture which has selective anti-lung cancer activity | |
JPH0971528A (en) | Antitumor agent | |
JPH09286737A (en) | Glycerophosphate dehydrogenase inhibitor |